Sarepta Therapeutics, Inc. (SRPT) Institutional Ownership

Ownership Summary

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has 337 institutional investors that have filed 13F reports for the period ending March 2026.

• These investors collectively held 937762.3% of Sarepta Therapeutics's outstanding shares in March 2026, up from 94.2% in December 2025.
• They increased total shares held in SRPT by 31.91% quarter over quarter, and investors in Sarepta Therapeutics decreased 22.17% from a year ago.
• Of these 337 holders, 162 added to their stakes in Sarepta Therapeutics, 126 trimmed positions, and 49 made no changes.
• Institutional investors collectively held 103.15Mn shares in Sarepta Therapeutics as of March 2026, up by 24.96Mn shares quarter on quarter, and up 11.51Mn shares year over year.
• BlackRock, Inc. holds the largest position in SRPT at 14.76Mn shares as of March 31, 2026, or 134138.88% of shares outstanding.
• Leading buyers of Sarepta Therapeutics shares for the quarter ending March 2026 were VANGUARD PORTFOLIO MANAGEMENT LLC (6.64Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.58Mn), RA CAPITAL MANAGEMENT, L.P. (3.9Mn), TWO SIGMA INVESTMENTS, LP (2.15Mn), FIRST TRUST ADVISORS LP (2.14Mn).
• Top sellers of SRPT stock for the quarter ending March 2026 included AQR CAPITAL MANAGEMENT LLC (1.36Mn), D. E. Shaw & Co., Inc. (1.07Mn), VOLORIDGE INVESTMENT MANAGEMENT, LLC (445.86K), NATIONAL BANK OF CANADA /FI/ (222.89K), Aquatic Capital Management LLC (194.61K).
• Business Quant data shows the 10 biggest positions in Sarepta Therapeutics as of March 2026 are held by BlackRock, Inc. (14.76Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (6.64Mn), State Street Corp (6.61Mn), AQR CAPITAL MANAGEMENT LLC (6.43Mn), TWO SIGMA INVESTMENTS, LP (4.59Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.58Mn), FIRST TRUST ADVISORS LP (4.14Mn), RA CAPITAL MANAGEMENT, L.P. (3.9Mn), Erste Asset Management GmbH (2.97Mn), Morgan Stanley (2.6Mn).